0
PublicationsContact
PublicationContact

First-in-class
cell therapies
for advanced
solid tumors

First-in-class
cell therapies
for advanced
solid tumors

Meet SLT

Redefining Cancer

Treatment

At Second Life Therapeutics, we are reshaping how difficult-to-treat and refractory solid tumors are approached, including cancers once considered “untreatable”

Our Breakthrough Therapy: SL‑28

We are a clinical-stage biopharmaceutical company advancing Leukocyte-Tells (SL‑28), the first-in-class, allogeneic, non-genetically modified adoptive cell therapy. SL‑28 therapy is tumor-agnostic, highly active against solid tumors, ready-to-use, and based on a New Biology concept overcoming the limitations of current approaches.

Therapies

The Science Behind SL‑28

Our scientists and medical team discovered the Universal Receptive System and its unique Teazeled receptors (TezRs) through which, for the first time, we can modulate cellular memory. We transform donor-derived immune cells into Leukocyte-Tells (SL‑28) that are capable of targeting a broad spectrum of solid tumors with unprecedented levels of response. Our science has unlocked anticancer mechanisms that were previously unknown.

Publication

Why SL-28

  • Cancer-agnostic

    01

    Designed to address multiple tumor types resistant to current therapies.

  • Ready-to-use

    02

    immediate access for patients, avoiding the long delays of custom manufacturing typical for other cell-therapies.

  • Refractory solid tumors

    03

    SL-28 works on “untreatable” and treatment-refractory solid tumors, and uses several novel anticancer mechanisms that were recently discovered by our team of scientists.

Who we are

?

Second Life Therapeutics is part of the Second Life Group, with our technology developed in close collaboration with Tetz Laboratories in New York. Together, we are pioneering a new generation of therapies that bring hope to patients facing the most challenging cancers.

Second Life Group

At Second Life Therapeutics,

we treat the most advanced

and refractory tumors, providing

a second chance at

life for patients in need"

Founders

Second Life Therapeutics is led by an accomplished team of physicians and scientists with extensive experience in biotechnology and drug development who consider their science as a form of art.

Professor

Victor Tetz

MD
PhD
Co-Founder, Chief Scientific Officer

George Tetz

MD
PhD
Co-Founder, Chief Scientific Officer

Location

New YorkCaliforniaAustralia

New York

Second Life Therapeutics is a global company with scientific sites on two continents in the United States and Australia, aimed to bring the innovation of the Universal Receptive System to those in need.

USA, New York, 101 Avenue of the Americas
3rd Floor, NY 10013
+1 …-…-….
Corporate headquarters

California

Manufacturing

Second Life Therapeutics partners with leading manufacturing experts to ensure that Leukocyte-Tells (SL-28) reach patients rapidly, reliably, and at the highest quality.

Safety and Quality

Working hand in hand with the manufacturing facility, Second Life Therapeutics team oversees every stage of clinical-grade production and quality control. This guarantees consistency, safety, and reproducibility across all batches.

Supporting Patients and Trials

With the integrated approach, we deliver a dependable supply of SL-28 to power our clinical development programs and to patients receiving treatment through expanded access pathway.

Australia

Australia, Second LIfe Therapeutics
L2 169 Pirie ST, Adelaide SA 5000
+61 39 245 1001
Clinical development
  1. Therapies
  2. Clinical Trials
  3. Pipeline

VictorTetz

Victor Tetz, M.D., Ph.D., is cofounder and chief scientific officer at Second Life Therapeutics.

Throughout his career, Dr. Victor Tetz made multiple breakthrough discoveries related to microbiology and cell regulation further developed by NASA, P&G, Dole, PepsiCo, and others. Prior to joining Second Life Therapeutics, Dr. Victor Tetz was a professor of microbiology and spent over four decades in academia. His research centered on host reactions to cell regulation, microbiome, and microbial virulence.

Dr. Victor Tetz was the first to determine the number of RNA genome fragments in the influenza virus, discover previously unknown bacterial species, and demonstrate the biological importance of minor DNA components in cellular processes.

He pioneered the study of multicellular behavior in bacteria, being the first to describe the structure and composition of the microbial biofilm surface layer and to develop early methods for targeting the biofilm matrix as a new approach to antimicrobial therapy.

Among his most groundbreaking discoveries is the identification of the previously unknown Universal Receptive System and TezR receptors. He also uncovered novel mechanisms regulating cell memory, paving the way for the development of next-generation therapeutic modalities.
With this discovery, Dr. Tetz is modulating cellular memory for the first time, bringing cell control to a new and unprecedented level.

He serves as Head of the Human Microbiology Institute, where he plays an integral role in numerous breakthrough discoveries.

GeorgeTetz

George Tetz, M.D., Ph.D., joined Second Life Therapeutics in June 2023 as Chief Executive Officer and Board Member.

As a renowned figure in the New York biotech industry, Dr. George Tetz has dedicated his life’s work to addressing some of medicine’s most critical unmet needs.  Throughout his career as both a medical practitioner and researcher, Dr. Tetz has focused on applying cutting-edge multifactorial approaches to a variety of medical problems. He discovered previously unknown bacteria that cause human diseases and developed the first methods to target the microbial biofilm matrix as a novel therapeutic approach to antimicrobial therapy.

One of his most groundbreaking findings is the existence of the previously unknown Universal Receptive System and Teazeled receptors. With this discovery, Dr. Tetz is modulating cellular memory for the first time, bringing cell control to a new and unprecedented level.

Second Life Therapeutics is led by an accomplished team of physicians and scientists with extensive experience in biotechnology and drug development who consider their science as a form of art.